Identification of HumanEther-à-go-goRelated Gene Modulators by Three Screening Platforms in an Academic Drug-Discovery Setting
- 1 December 2010
- journal article
- research article
- Published by Mary Ann Liebert Inc in ASSAY and Drug Development Technologies
- Vol. 8 (6), 727-742
- https://doi.org/10.1089/adt.2010.0331
Abstract
The human Ether-à-go-go related gene (hERG) potassium channel is responsible for the rapid delayed rectifier potassium current that plays a critical role in the repolarization of cardiomyocytes during the cardiac action potential. In humans, inhibition of hERG by drugs can prolong the electrocardiographic QT interval, which, in rare instance, leads to ventricular arrhythmia and sudden cardiac death. As such, several medications that block hERG channels in vitro have been withdrawn from the market due to QT prolongation and arrhythmias. The current FDA guidelines recommend that drug candidates destined for human use be evaluated for potential hERG activity (www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm074963.pdf). Here, we employed automated planar patch clamp (APPC), high-throughput fluorescent Tl+ flux, and moderate-throughput [3H]dofetilide competition binding assays to characterize a panel of 49 drugs for their activities at the hERG channel. Notably, we used the same HEK293-hERG cell line for all assays, facilitating comparisons of hERG potencies across screening platforms. In general, hERG inhibitors were most potent in APPC assays, intermediate potent in [3H]dofetilide binding assays, and least potent in Tl+ flux assays. Binding affinity constants (pKi values) and Tl+ flux potencies (pEC50 values) correlated well with APPC pEC50 values. Further, the inhibitory potencies of many known hERG inhibitors in APPC matched literature values from manual and/or automated patch clamp systems. We also developed a novel fluorescent Tl+ flux assays to measure the effects of drugs that modulate hERG trafficking and surface expression.Keywords
This publication has 56 references indexed in Scilit:
- Extracellular K + Is a Prerequisite for the Function and Plasma Membrane Stability of HERG ChannelsCirculation Research, 2010
- Cell-Based Potassium Ion Channel Screening Using the FluxOR™ AssaySLAS Discovery, 2010
- Hsp40 Chaperones Promote Degradation of the hERG Potassium Channel*Online Journal of Public Health Informatics, 2010
- Drug‐induced QT interval shortening: potential harbinger of proarrhythmia and regulatory perspectivesBritish Journal of Pharmacology, 2010
- PD-118057 contacts the pore helix of hERG1 channels to attenuate inactivation and enhance K + conductanceProceedings of the National Academy of Sciences of the United States of America, 2009
- Inhibition of HIV-1 gene expression by Ciclopirox and Deferiprone, drugs that prevent hypusination of eukaryotic initiation factor 5ARetrovirology, 2009
- Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cellsBlood, 2009
- Current challenges in the evaluation of cardiac safety during drug development: Translational medicine meets the Critical Path InitiativeAmerican Heart Journal, 2009
- Extracellular K+ concentration controls cell surface density of IKr in rabbit hearts and of the HERG channel in human cell linesJCI Insight, 2009
- PKA phosphorylation of HERG protein regulates the rate of channel synthesisAmerican Journal of Physiology-Heart and Circulatory Physiology, 2009